Prevention of Dystrophic Pathology in Severely Affected Dystrophin/Utrophin-deficient Mice by Morpholino-oligomer-mediated Exon-skipping
Open Access
- 1 January 2010
- journal article
- research article
- Published by Elsevier BV in Molecular Therapy
- Vol. 18 (1), 198-205
- https://doi.org/10.1038/mt.2009.248
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept studyThe Lancet Neurology, 2009
- Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomerProceedings of the National Academy of Sciences, 2008
- Microutrophin Delivery Through rAAV6 Increases Lifespan and Improves Muscle Function in Dystrophic Dystrophin/Utrophin-deficient MiceMolecular Therapy, 2008
- Sustained Dystrophin Expression Induced by Peptide-conjugated Morpholino Oligomers in the Muscles of mdx MiceMolecular Therapy, 2008
- Myostatin Propeptide Gene Delivery by Adeno-Associated Virus Serotype 8 Vectors Enhances Muscle Growth and Ameliorates Dystrophic Phenotypes inmdxMiceHuman Gene Therapy, 2008
- Behavioural characterisation of the robotic mouse mutantBehavioural Brain Research, 2007
- Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathologyNature Medicine, 2006
- Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotideThe Journal of Gene Medicine, 2005
- Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophyThe Journal of Gene Medicine, 2002
- Power Output of Fast and Slow Skeletal Muscles of MDX (Dystrophic) and Control Mice After Clenbuterol TreatmentExperimental Physiology, 2000